Business · 07/12/2016Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for GARDASIL 9 Patent Extension
Summary
The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for GARDASIL 9, a human biological product, in response to patent extension applications submitted to the U.S. Patent and Trademark Office (USPTO).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →